• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vifor Pharma Group

Extension of the postponement of the settlement of Vifor Pharma tender offer
July 13, 2022
From Vifor Pharma Group
Via Business Wire
Update on the timeline for Vifor Pharma tender offer
May 12, 2022
From Vifor Pharma Group
Via Business Wire
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
April 28, 2022
From Vifor Pharma Group
Via Business Wire
94th Vifor Pharma Group Annual General Meeting
April 26, 2022
From Vifor Pharma Group
Via Business Wire
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
April 04, 2022
From Vifor Pharma Group
Via Business Wire
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
March 23, 2022
From Vifor Pharma Group
Via Business Wire
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
February 28, 2022
From Vifor Pharma Group
Via Business Wire
Vifor Pharma appoints two new members to the Executive Committee
February 02, 2022
From Vifor Pharma Group
Via Business Wire
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
December 20, 2021
From Vifor Pharma Group
Via Business Wire
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
December 16, 2021
From Vifor Pharma Group
Via Business Wire
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
December 14, 2021
From Vifor Pharma Group
Via Business Wire
Vifor Pharma comments on media speculation
December 13, 2021
From Vifor Pharma Group
Via Business Wire
Vifor Pharma comments on market speculations
December 02, 2021
From Vifor Pharma Group
Via Business Wire
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis
November 12, 2021
From Vifor Pharma Group
Via Business Wire
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
September 27, 2021
From Vifor Pharma Group
Via Business Wire
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
September 16, 2021
From Vifor Pharma Group
Via Business Wire
Tickers TVTX
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines
August 31, 2021
From Vifor Pharma Group
Via Business Wire
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
August 24, 2021
From Vifor Pharma Group
Via Business Wire
Tickers CARA
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
April 30, 2021
From Vifor Pharma Group
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap